Galleri is a cancer detection test by Grail. The test is not yet approved by the FDA (Grail)

Hims adds cancer detection test to Labs product

Its lab analysis product will be a central part of the company’s upcoming Super Bowl ad.

2/4/26 9:00AM

Hims & Hers will add Galleri, a cancer detection test made by Grail, to its offerings as it works to expand its Labs product.

Hims said Wednesday that it would add the blood test, which says it detects signals for over 50 types of cancer before symptoms appear, to its portfolio. It comes at a $250 discount to the Galleri list price, which is $949, but it’s available only to Labs subscribers.

Hims rose by as much as 5% early trading following the announcement after several days of declines.

Hims launched its lab analysis product, which is a central part of its upcoming Super Bowl commercial, in November. The advertisement unveiled last week alluded to a cancer detection product. Grail announced in October that it raised $325 million from several investors, including Hims. The company did not give specifics of its business relationship with Grail or how the investment plays into it.

Hims’ labs product initially marketed two tiers: a base plan that costs $199 per year or an advanced plan for $499. It now offers a single plan at $349 a year. It’s one of several product expansions the company has announced as it pivots focus away from weight-loss treatments.

Screenshot 2026-02-02 at 3.39.18 PM — A screen shot of Hims & Hers’ upcoming Super Bowl commercial posted on January 29, 2026 (Sherwood News)

Grail has sold roughly 185,000 Galleri tests as of the end of 2025, according to a recent presentation the company gave at the JPMorgan Healthcare Conference in San Francisco. The Galleri tests brought in between $138 million and $139 million in revenue last year, up from $109 million in 2024.

Grail announced Thursday that it filed for Food and Drug Administration approval of its Galleri test. The test has been available commercially since 2021, but approval from the FDA could position it to be covered by major insurers.

The test has been available through partners like Quest Diagnostics and Function Health, a lab analysis startup offering a similar product to Hims, which announced it would offer Galleri tests in December.

Correction: An earlier version of this story provided outdated Hims Labs' pricing tiers.

Hyunsoo Rim

appy birthday

4/1/26

Apple is turning 50 today and it doesn’t look a thing like its younger self

From Macs to iPods, iPhones, and now services, here’s how Apple’s business has looked every 10 years.

The entrance of Allbirds seen from Hayes St. in San Francisco, Calif.

Allbirds, the once buzzy multibillion-dollar sneaker startup, is selling up for $39 million

That’s less than 1% of its peak market cap about four years ago.

Tom Jones3/31/26

Max Knoblauch3/30/26

JetBlue is raising its bag fees as fuel costs squeeze airlines

JetBlue will reportedly hike its bag fees, as the cost of jet fuel continues to climb amid the war in Iran. It’s the latest example of carriers finding ways to push rising costs onto travelers.

Last week, United Airlines CEO Scott Kirby said that if fuel prices remain elevated, fares would need to rise another 20% for his airline to break even this year.

As CNBC reported, when one airline raises fees, others tend to follow.

Earlier this month, JetBlue hiked its first-quarter outlook for operating revenue per seat mile to between 5% and 7%, saying that strong Q1 demand helped “partially offset additional expenses realized from operational disruptions and rising fuel costs.” Now, the carrier appears to be making moves to further boost revenue to offset those costs.

Earlier on Monday, JetBlue rival Alaska Air lowered its Q1 profit forecast. The refining margins for the carrier’s cheapest fuel option — sourced from Singapore and representing about 20% of Alaska’s overall supply — have spiked 400% since February.

JetBlue did not immediately respond to a request for comment.